Pharming Group NV and Swedish Orphan Biovitrum AB (Sobi) has signed an amendment of their Ruconest distribution agreement from 2009.
In addition to Austria, Germany and Netherlands, Pharming will market Ruconest directly into an additional 21 countries, effective 1 October 2016. These countries include Algeria, Andorra, Bahrain, Belgium, France, Ireland, Jordan, Kuwait, Lebanon, Luxembourg, Morocco, Oman, Portugal, Qatar, Syria, Spain, Switzerland, Tunisia, United Arab Emirates, United Kingdom, and Yemen.
To support the commercialization, Pharming will expand the current small European team of experienced HAE marketing and medical affairs specialists.
To ensure a seamless hand-over and guarantee the continuous availability of Ruconest to patients, Sobi will continue to deliver Ruconest and continue the drug safety monitoring and reporting, until 1 October 2016.
Sijmen de Vries, Pharming’s CEO, commented, “The extension of our direct commercialization of Ruconest into these additional 21 markets is a further step towards our goal of becoming a specialty pharma company with significant commercial infrastructure to be able to fully benefit from the added value of bringing our products to patients. Despite Ruconest sales in these important markets being modest, this move is expected to have a positive impact on our financial performance as we will be able to improve the margin from sales with every vial of Ruconest sold.